The Chain Consists Of Two Or More Carbons Which Are Unsubtituted Or Have Acyclic Hydrocarbyl Substituents Only Patents (Class 514/654)
  • Patent number: 10502688
    Abstract: Provided are methods and systems for identification and analysis of materials and molecular structures. An apparatus for identification and analysis of materials and molecular structures may include a laser. The laser may, in turn, include an amplified spontaneous emission-suppressed single-frequency laser excitation source. The apparatus may further comprise a plurality of filters. The plurality of filters may include reflective volume holographic grating blocking filters. The apparatus may also comprise an optical unit and an optical spectrometer. The optical unit may be configured to deliver excitation energy to a sample substance and capture Raman signal scattering from the sample substance. The optical spectrometer may be disposed in a path of the Raman signal and configured to measure a spectrum of the Raman signal and generate a detection signal. Finally, the apparatus may comprise a processing unit configured to analyze the spectrum.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: December 10, 2019
    Assignee: Ondax, Inc.
    Inventors: James Carriere, Lawrence Ho, Frank Havermeyer, Eric Maye, Randy Heyler
  • Patent number: 10471015
    Abstract: The present invention relates generally to abuse-deterrent formulations containing dextroamphetamine sulfate.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: November 12, 2019
    Assignee: Vallon Pharmaceuticals, Inc.
    Inventors: Yaron Daniely, David Baker, Hanna Ron, David Siner
  • Patent number: 10464873
    Abstract: A high yield process of preparation of [1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethy]-cyclohexanol] through potassium salt mediated demethylation of [1-[2-(Dimethyl amino-1-(4-methoxyphenyl) ethyl cyclohexanol] in monoethylene glycol under phase transfer conditions, as well as the preparation of salt of [1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]-cyclohexanol].
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: November 5, 2019
    Assignee: R L FINECHEM PRIVATE LIMITED
    Inventors: Ramesha A. Ramakrishna, Siddegowda S. Maravanahalli
  • Patent number: 10292948
    Abstract: Disclosed herein are pharmaceutical compositions for nasal administration comprising tapentadol, their preparation and their use in the treatment of pain.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: May 21, 2019
    Assignee: Torrent Pharmaceuticals Limited
    Inventors: Jaya Abraham, Vivek Mishra, Vipul Mittal, Kiran Chaudhari
  • Patent number: 10105326
    Abstract: The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its formulation to its administration.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: October 23, 2018
    Assignees: Centre Hospitalier Regional Et Universitaire De Lille (Chru), Universite De Lille 2 Droit Et Sante, Universite Du Littoral Cote D'Opale
    Inventors: David Devos, Caroline Moreau, Charlotte Laloux, Jean-christophe Devedjian
  • Patent number: 9931303
    Abstract: The present invention relates generally to abuse-deterrent formulations containing dextroamphetamine sulfate.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: April 3, 2018
    Assignee: Alcobra Ltd.
    Inventors: Yaron Daniely, David Baker, Hanna Ron, David Siner
  • Patent number: 9480661
    Abstract: An orally disintegrating tablet which can be chewed or disintegrated by contact with saliva and containing weight-loss drugs for weight control in humans, especially in children and adolescents, is disclosed.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: November 1, 2016
    Assignee: Alpex Pharma S.A.
    Inventors: Federico Stroppolo, Shahbaz Ardalan
  • Patent number: 9415086
    Abstract: Methods and compositions for activating an EphA receptor can be used for identifying therapeutic agents for cancer.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: August 16, 2016
    Inventors: Bingchen Wang, Eugene Myshkin, Hui Miao
  • Patent number: 9238020
    Abstract: A method of providing a patient with controlled release of tapentadol using a prodrug capable, upon enzymatic activation and intramolecular cyclization, of releasing tapentadol is disclosed. The disclosure also provides such prodrug compounds and pharmaceutical compositions comprising such compounds. Such pharmaceutical compositions can optionally include an enzyme inhibitor that interacts with the enzyme(s) to mediate the enzymatically-controlled release of tapentadol from the prodrug so as to modify enzymatic cleavage of the prodrug. Also included are methods to use such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: January 19, 2016
    Assignee: Signature Therapeutics, Inc.
    Inventors: Thomas E. Jenkins, Julie D. Seroogy, Jonathan W. Wray
  • Publication number: 20150148355
    Abstract: A silicone gel (“silogel”) composition used to deliver pharmaceutical products transdermally as well as a method for producing the silogel composition, which may contain up to 80% additive ingredients. Preferred embodiments of the invention may include silogel compositions which provide high viscosity/no separation due to API. They are not temperature-sensitive, have no shear stress from the ointment mill/EMP, have no gumming up/stickiness, and no hardening.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventor: John Olin Trimble
  • Publication number: 20150118301
    Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
    Type: Application
    Filed: September 4, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Publication number: 20150118295
    Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
    Type: Application
    Filed: September 12, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Publication number: 20150118302
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Application
    Filed: October 29, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Publication number: 20150118300
    Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
    Type: Application
    Filed: July 17, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Patent number: 9012689
    Abstract: The present invention relates to a compound of formula A, wherein R is alkyl. Compound A may be used as an intermediate in the preparation of O-desmethyl venlafaxine or a salt thereof, and the present invention provides such a preparation, as well as a process for preparing the compound of formula A.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: April 21, 2015
    Assignee: Cipla Limited
    Inventors: Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao, Manohar Raghunath Surve
  • Publication number: 20150104495
    Abstract: Described are transdermal drug delivery compositions comprising amphetamine, methods of manufacturing transdermal drug delivery compositions comprising amphetamine, and therapeutic methods using transdermal drug delivery compositions comprising amphetamine, such as may be desired for achieving central nervous system stimulation, such as for the treatment of attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), or for the treatment of narcolepsy. In some embodiments, the compositions comprise an amount of polyurethane effective to control the presence of and/or prevent the formation of phenyl acetone in the compositions. The polyurethane may be present in a drug-containing polymer matrix or in a backing adjacent the drug-containing polymer matrix.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 16, 2015
    Applicant: Noven Pharmaceuticals, Inc.
    Inventors: Viet Nguyen, Steven DINH, Jun LlAO, Robert L. LAMBERT
  • Publication number: 20150105433
    Abstract: Provided herein are methods for preventing or treating a viral infection in a subject, wherein the viral infection is mediated by a virus comprising one or more viral RNA molecules translated by a ribosomal shunting mechanism or a non-IRES mediated mechanism. The methods comprise administering to a subject an agent that reduces ribosomal protein (Rps25) expression or function. Also provided are methods of inhibiting or promoting ribosomal shunting-mediated translation or non-IRES mediated translation. Also provided are methods of screening for an agent that inhibits or promotes ribosomal shunting-mediated translation or non-IRES mediated translation.
    Type: Application
    Filed: April 25, 2013
    Publication date: April 16, 2015
    Inventor: Sunnie R. Thompson
  • Publication number: 20150099741
    Abstract: Disclosed are methods and kits for diagnosing, prognosing, and treating patients having psychiatric disorders. The methods may include assessing whether a patient has a treatment resistant psychiatric disorder or assessing whether the patient is likely to develop a treatment resistant psychiatric disorder. The methods may include detecting genetic markers such as the single nucleotide polymorphism (SNP) in genes present in a genomic nucleic acid sample from the patient, and/or receiving, as a caregiver, the results of tests indicating whether the genetic markers are present in the genomic nucleic acid sample from the patient. The methods may include administering treatment to the patient, for example, based on the detected genetic markers, and administering treatment may include administering new antipsychotic drugs (APDs) that are trace amine-associated receptor 1 (TAAR1) agonists.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Applicant: Northwestern University
    Inventors: Jiang Li, Herbert Y. Meltzer
  • Patent number: 9000216
    Abstract: An optically active spirolactone compound is highly enantioselectively produced by using an iodoarene derivative which can be synthesized easily and which is not racemized easily. A hypervalent iodine compound precursor (iodoarene derivative) which was able to be designed flexibly was synthesized from 2,6-dihydroxyiodoarene by using 1,2-aminoalcohol as a chiral source in short steps, a hypervalent iodine compound was prepared in a reaction system (in situ) by using a catalyst quantity of the resulting precursor in the presence of a stoichiometric quantity of m-CPBA, and a spirolactonization reaction of 3-(1-hydroxy-2-naphthyl)propionic acid was induced. As a result, a corresponding spirolactone compound was obtained at a high enantiomeric excess.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: April 7, 2015
    Assignee: National University Corporation Nagoya University
    Inventors: Kazuaki Ishihara, Muhammet Uyanik, Takeshi Yasui
  • Publication number: 20150094343
    Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.
    Type: Application
    Filed: June 4, 2014
    Publication date: April 2, 2015
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Waldemar PRIEBE, Izabela FOKT, Slawomir SZYMANSKI, Timothy MADDEN, Jeffrey MYERS, Charles CONRAD
  • Publication number: 20150093436
    Abstract: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventors: Gopi M. VENKATESH, James M. CLEVENGER
  • Publication number: 20150086626
    Abstract: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed along with a method of preparation therefor. The dosage form comprises active core particles which are individually surrounded by a water insoluble polymer coating which lacks plasticizer.
    Type: Application
    Filed: April 16, 2013
    Publication date: March 26, 2015
    Inventors: Thomas Daniel Reynolds, Boyong Li
  • Patent number: 8986664
    Abstract: The invention provides a method for improving hair biology, e.g., hair growth. The method comprises administering to a subject a monoamine oxidase inhibitor and a vasodilator, a zinc salt of a carboxylic acid, a xanthine compound, pyrithione or a salt thereof, saponin, tritapene, crataegolic acid, celastrol, asiatic acid, an inhibitor of 5-alpha-reductase, 1,4-methyl-4-azasteroid, an androgen receptor antagonist, azelaic acid or a derivate thereof, cyclosporin, triiodothyronine, diazoxide, retinoic acid, a prostaglandin analog, aminexil, carnitine tartrate, apigenin, procapil, or adenosine, in an amount effective to achieve a desired effect. The invention further provides a method of reducing or delaying the appearance of an age-related skin imperfection. The method comprises administering to the subject a composition comprising an MAO inhibitor. A kit for improving hair growth also is provided.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: March 24, 2015
    Assignee: The Procter & Gamble Company
    Inventors: Teresa DiColandrea, Robert Scott Youngquist, Sancai Xie, Robert Lloyd Binder, Gary Richard Fuentes, Deborah Lade
  • Publication number: 20150080474
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising a pharmaceutically active amphetamine salt covered with an immediate-release coating and a pharmaceutically active amphetamine salt covered with an enteric coating wherein the immediate release coating and the enteric coating provide for multiple pulsed dose delivery of the pharmaceutically active amphetamine salt. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Application
    Filed: September 26, 2014
    Publication date: March 19, 2015
    Inventors: Amir SHOJAEI, Stephanie READ, Richard A. COUCH, Paul HODGKINS
  • Publication number: 20150065581
    Abstract: The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine. The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 5, 2015
    Inventors: Seth Lederman, Herb Harris
  • Patent number: 8969299
    Abstract: Methods for modulating serum phosphorus levels are described, wherein calcimimetic agents are administered to a subject in need thereof. In one embodiment, the compound is cinacalcet, and in other embodiments the compound is comprised of a contiguous sequence of subunits, X1—X2—X3—X4—X5—X6—X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits. The compound, when administered at selected times to a patient undergoing dialysis, lowers serum phosphorus levels, relative to pre-dosing levels, and achieves a sustained reduced level for a period of time after administration.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: March 3, 2015
    Assignee: KAI Pharmaceuticals, Inc.
    Inventors: Felix Karim, Gregory Bell
  • Patent number: 8962014
    Abstract: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, comprising: a) a cover layer, b) a reservoir present on the cover layer, comprising a polymer matrix comprising the active substance, c) an adhesive layer present on the reservoir comprising a contact adhesive, and d) a removable layer present on the adhesive layer, the active substance being rivastigmine, a physiologically compatible salt, hydrate, solvate or derivative thereof, characterized in that the polymer matrix of the reservoir comprises neither hydroxyl groups nor carboxyl groups.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: February 24, 2015
    Assignee: Acino AG
    Inventors: Heike Prinz, Björn Schurad, Thomas Beckert, Kristina Linder
  • Patent number: 8957067
    Abstract: A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: February 17, 2015
    Assignee: Pisgah Laboratories, Inc.
    Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
  • Publication number: 20150045444
    Abstract: Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventors: Ian Leslie Scott, Vladimir Aleksandrovich Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Jennifer Gage, Feng Hong
  • Publication number: 20150045437
    Abstract: Provided are kits containing a base composition and an active pharmaceutical ingredient for transdermal delivery of active pharmaceutical ingredients. Examples of active pharmaceutical ingredients include amitriptyline, baclofen, cyclobenzaprine HCl, ibuprofen, lidocaine HCl, naproxen and tramadol, ketoprofen, diclofenac, phenylbutazone, mefenamic acid, flubiprofen, piroxicam, guaifenasin, prilocaine, bupivicaine, tetracaine, nifedipine, verapamil, orphenadrine, imipramine, ketamine, gabapentin, carbamazepine, menthol, capsaicin, clonidine, dexamethasone, dextromethorphan, testosterone, progesterone, and estrogens.
    Type: Application
    Filed: August 8, 2014
    Publication date: February 12, 2015
    Inventor: Robert Prentice Nickell
  • Publication number: 20150045388
    Abstract: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy is disclosed.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventor: Ronald AUNG-DIN
  • Patent number: 8946302
    Abstract: The invention provides compounds of the formulas described herein and compositions thereof. The invention further provides methods of using the compounds and compositions. The compounds of the invention can provide high affinity binding to sigma-1 receptors in a mammal. The compounds can exhibit selectivity for the sigma-1 receptor over the sigma-2 receptor. The compounds and compositions of the invention can also be used to treat conditions that involve the sigma-1 receptor, such as addiction, cardiovascular conditions, and cancer, for example, cancer of the breast, lung, prostate, ovarian, colorectal, or the CNS.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: February 3, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Arnold E. Ruoho, Abdol R. Hajipour, Uyen B. Chu, Dominique A. Fontanilla
  • Publication number: 20150031719
    Abstract: The invention is directed to topical formulations and methods of treating a migraines and/or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations thereof, pharmaceutically acceptable salt thereof, prodrugs thereof or derivative thereof.
    Type: Application
    Filed: October 10, 2014
    Publication date: January 29, 2015
    Inventor: Ronald AUNG-DIN
  • Publication number: 20150025086
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Publication number: 20150018426
    Abstract: The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety.
    Type: Application
    Filed: September 30, 2014
    Publication date: January 15, 2015
    Inventors: Ilona STEIGERWALD, Ulrich JAHNEL, Thomas TZSCHENTKE
  • Patent number: 8933123
    Abstract: The present invention discloses polymorphic forms of O-desmethyl-venlafaxine succinate and processes for the preparation thereof.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: January 13, 2015
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Ashok Prasad, Rushikesh Udaykumar Roy
  • Patent number: 8927010
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: January 6, 2015
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Publication number: 20150005291
    Abstract: Cosmetic skin and hair care compositions for enhancing the growth and appearance of mammalian hair in an individual are provided, which compositions comprise a dose of an L-type calcium channel blocker effective to promote anagen phase of the hair cycle. As shown herein, anagen phase promotion can result in more rapid hair growth.
    Type: Application
    Filed: February 8, 2013
    Publication date: January 1, 2015
    Inventors: Anthony Oro, Ricardo Ei Dolmetsch, Gozde Yucel
  • Patent number: 8920837
    Abstract: The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration.
    Type: Grant
    Filed: July 3, 2006
    Date of Patent: December 30, 2014
    Assignee: Rubicon Research Private Limited
    Inventors: Pratibha S. Pilgaonkar, Maharukh T. Rustomjee, Anilkumar S. Gandhi, Paras R. Jain, Atul A. Kelkar
  • Publication number: 20140377322
    Abstract: Disclosed is a multi-layered structure for drug reservoir, comprising a first micelle layer for crosslinking and adhesion, comprising a drug, a multi-arm polymer, a phenol derivative, and a dopa derivative and having a one or two-layered structure; a second micelle layer for crosslinking, being stacked on the first micelle layer, comprising a drug, a multi-arm polymer, and a phenol derivative, and having a one or two-layered structure; and a physiologically active material layer, being stacked on the second micelle layer, comprising a physiologically active material, a water-soluble polymer, and a phenol derivative, and having a one or two-layered structure.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 25, 2014
    Inventors: Ki Dong PARK, Jong Hoon CHOI
  • Publication number: 20140378473
    Abstract: This invention relates to novel diarylamino compounds that bind to the sigma-2 receptor, to pharmaceutical compositions comprising such compounds, and to methods for inhibiting or restoring synapse loss in neuronal cells, modulating a membrane trafficking change in neuronal cells, and treating cognitive decline and neurodegenerative diseases and disorders therewith.
    Type: Application
    Filed: August 27, 2012
    Publication date: December 25, 2014
    Applicant: COGNITION THERAPEUTICS, INC.
    Inventors: Susan M. Catalano, Gilbert Rishton, Nicholas J. Izzo
  • Patent number: 8916588
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: December 23, 2014
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 8916596
    Abstract: An embodiment of the invention provides preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating reactivation of a virus after latency in a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, comprising administering to the mammal an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor before, during, and/or after the organ or tissue transplant. The viral infection may be due to a herpesvirus, such as herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), varicella zoster virus (VZV), or cytomegalovirus (CMV).
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: December 23, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Thomas Kristie, Yu Liang
  • Patent number: 8916587
    Abstract: A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: December 23, 2014
    Assignee: Pisgah Laboratories, Inc.
    Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
  • Publication number: 20140371229
    Abstract: The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network. In particular, the invention relates to compounds which, alone or in combination(s), can effectively protect neuronal cells from alpha-synuclein aggregates. The invention also relates to methods of producing a drug or a drug combination for treating Parkinson's disease and to methods of treating Parkinson's disease or a related disorder.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 18, 2014
    Inventors: DANIEL COHEN, SERGUEI NABIROCHKIN, ILYA CHUMAKOV, RODOLPHE HAJJ
  • Publication number: 20140371324
    Abstract: Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.
    Type: Application
    Filed: June 2, 2014
    Publication date: December 18, 2014
    Applicant: COGNITION THERAPEUTICS, INC.
    Inventors: Gilbert M. RISHTON, Susan CATALANO
  • Patent number: 8912217
    Abstract: A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: December 16, 2014
    Assignee: Pisgah Laboratories, Inc.
    Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
  • Publication number: 20140357667
    Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.
    Type: Application
    Filed: August 6, 2014
    Publication date: December 4, 2014
    Inventors: Bruce Roseman, Gilla Kaplan
  • Publication number: 20140350118
    Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.
    Type: Application
    Filed: June 5, 2014
    Publication date: November 27, 2014
    Inventors: Bhushan Hardas, Donna Dalton
  • Patent number: 8895623
    Abstract: The present invention relates to a method of providing pain management in a subject wherein the administration of the composition does not result in any non-central nervous system mediated systemic effect in the subject. In particular, the present invention relates to a method of administering 3-[(1S,2S)-3-(dimethylamino)-1-ethyl-2-methyl-propyl]-phenol in a space that is void of thrombocytes.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: November 25, 2014
    Assignee: Gruenenthal GmbH
    Inventors: Petra Bloms-Funke, Derek John Saunders, Eric Lang